Navigation Links
Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
Date:1/22/2008

Fourth Quarter 2007 Financial Results

VANCOUVER, Jan. 22 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, will host a conference call discussing its financial results for the fourth quarter and year ended December 31, 2007.

Thursday, February 14, 2008 at 11:00 AM ET

(8:00 AM Pacific, 9:00 AM Mountain, 10:00 AM Central)

Dial information is as follows:

North America (toll-free): (866) 510-0711

International: (617) 597-5379

Enter passcode: 91184096

A live webcast will be available to all interested parties through Angiotech's website at http://www.angiotech.com in the Investor Relations section.

A press release announcing Angiotech's financial results will be issued prior to the conference call at approximately 8:00 AM ET (5:00 AM Pacific, 6:00 AM Mountain, 7:00 AM Central).

A replay archive of the conference call will be available until February 21, 2008.

Replay information is as follows:

North America: (888) 286-8010

International: (617) 801-6888

Enter passcode: 85112963

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX, ANP) please visit our website at http://www.angiotech.com.

CONTACT: Jodi Regts, Senior Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930, jregts@angio.com; Deirdre Neary, Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech and Symphony Medical Announce Licensing Agreement
2. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
3. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
4. Angiotech to participate in RBC 2007 Healthcare Conference
5. Angiotech to participate in Bank of America 2007 Credit Conference
6. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
7. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
8. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
9. Angiotech to participate in UBS Global Life Sciences Conference
10. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
11. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):